Q2 2023 13F Holders as of 6/30/2023
-
Type / Class
-
Equity / COMMON STOCK
-
Shares outstanding
-
106M
-
Number of holders
-
152
-
Total 13F shares, excl. options
-
54.5M
-
Shares change
-
+3.1M
-
Total reported value, excl. options
-
$1.17B
-
Value change
-
+$53.6M
-
Put/Call ratio
-
0.32
-
Number of buys
-
95
-
Number of sells
-
-64
-
Price
-
$21.57
Significant Holders of Amylyx Pharmaceuticals, Inc. - COMMON STOCK (AMLX) as of Q2 2023
196 filings reported holding AMLX - Amylyx Pharmaceuticals, Inc. - COMMON STOCK as of Q2 2023.
Amylyx Pharmaceuticals, Inc. - COMMON STOCK (AMLX) has 152 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 54.5M shares
of 106M outstanding shares and own 51.21% of the company stock.
Largest 10 shareholders include VANGUARD GROUP INC (4.93M shares), PERCEPTIVE ADVISORS LLC (4.87M shares), BlackRock Inc. (3.51M shares), VIKING GLOBAL INVESTORS LP (2.96M shares), Boxer Capital, LLC (2.08M shares), MARSHALL WACE, LLP (1.98M shares), MILLENNIUM MANAGEMENT LLC (1.92M shares), D. E. Shaw & Co., Inc. (1.59M shares), Rock Springs Capital Management LP (1.54M shares), and FEDERATED HERMES, INC. (1.53M shares).
This table shows the top 152 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.